News
-
-
PRESS RELEASE
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
Sanofi and Regeneron's Dupixent approved in the US as the first medicine for allergic fungal rhinosinusitis, supported by phase 3 study. A breakthrough in treating chronic sinus disease -
-
-
-
PRESS RELEASE
Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
Sanofi and Teva's duvakitug phase 2b maintenance data show durable efficacy in ulcerative colitis and Crohn's disease. Results reinforce ongoing phase 3 programs in UC and CD -
-
-
PRESS RELEASE
Press Release: Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season
Universal RSV immunization with Beyfortus reduces hospitalizations in infants across two seasons, as per study in The Lancet Infectious Diseases and RSVVW '26 conference findings -
